title: Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers.
abstract: OBJECTIVE
  To compare the diagnostic validity of NIA-AA criteria, for AD CSF biomarkers, with our own new criteria.
  
  
  METHODS
  Between 2008 and 2011, 170 patients with Mild Cognitive Impairment (MCI) were included. CSF levels of Aβ1-42, T-tau, P-tau181, and ratios of T-tau/Aβ1-42 and P-tau181/Aβ1-42 were analyzed. In our criteria, we considered 3 or more abnormal variables indicative of a high likelihood of MCI due to AD.
  
  
  RESULTS
  After a clinical follow-up of 4.5 ± 1.2 years, 44 patients remained stable, 95 developed AD, 15 other forms of dementia, 7 died and 9 received other diagnoses. Using the NIA-AA criteria and our own criteria, the diagnostic validity of the CSF biomarkers was 58% versus 85%, specificity 84% versus 72%, PPV 82% versus 79% and NPV 61% versus 79%.
  
  
  CONCLUSIONS
  The inclusion of the ratios in diagnostic criteria increases sensitivity and NPV for the diagnosis of MCI due to AD.
authors.affiliation: 1 Department of Neurology, General University Hospital of Alicante, Alicante, Spain.
authors.forename: Maria Empar
authors.initials: ME
authors.lastname: Blanco-Cantó
authors.affiliation: 1 Department of Neurology, General University Hospital of Alicante, Alicante, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Monge-Argilés
authors.affiliation: 2 Neurology Section, Baix Vinalopó hospital, Elche, Alicante, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Pérez-Cejuela
authors.affiliation: 3 Denia Marina-Salud Regional Hospital, Alicante, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Badía
authors.affiliation: 3 Denia Marina-Salud Regional Hospital, Alicante, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Gabaldón
authors.affiliation: 4 Immunology Laboratory, General University Hospital of Alicante, Alicante, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Muñoz-Ruíz
authors.affiliation: 5 Department of Preventive Medicine, General University Hospital of Alicante, Alicante, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Payá
authors.affiliation: 1 Department of Neurology, General University Hospital of Alicante, Alicante, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Gasparini-Berenguer
authors.affiliation: 1 Department of Neurology, General University Hospital of Alicante, Alicante, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Leiva-Santana
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D060825:Cognitive Dysfunction / Q000134:cerebrospinal fluid*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D054561:National Institute on Aging (U.S.) / Q000592:standards; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D017410:Practice Guidelines as Topic / Q000592:standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014481:United States; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins
keywords: Alzheimer’s disease; CSF; biomarkers; diagnostic validity; mild cognitive impairment; ratios